PD-L1抗体目的:错配修复缺陷(Mismatch Repair Deficiency,d MMR)是肿瘤免疫检查点阻断(Immune Checkpoint Blockade,ICB)治疗反应的生物标志物之一,且与肿瘤组织起源无关.然而,所有肿瘤类型中只有不到15%的患者具有d MMR特征.因此,如何将MMR功能正常型(MMR-Proficient,p MMR)转化为d MMR表型以使肿瘤对ICB治疗敏感的...
Breast cancer (BC) is the most common cancer diagnosed in women worldwide. BC stem cells (BCSCs) have been known to be involved in the carcinogenesis of the breast and contribute to therapeutic resistance. The programmed death-ligand 1 (PD-L1) expression
Nuclear PD-L1 regulated gene expression of NF-κB signaling (BIRC3, RelB, and TRAP1), major histocompatibility complex (MHC) class I (human leukocyte antigen (HLA)-A, HLA-B, and HLA-H), and immune checkpoint (PD-L2, VISTA, and B&-H3) [29]. The NF-κB pathway is a crucial fact...
CD274编码细胞程序性死亡-配体1 (programmed death-ligand 1, PD-L1),在三阴性乳腺癌中使用JQ1既可降低PD-L1的表达水平,又有助于缓解免疫抑制[15]。JQ1还可以干扰乙酰化RelA和Brd4之间的相互作用,抑制Nf-κb活化和Nf-κb依赖性靶基因的表达,从而对Nf-κb依赖性肿瘤起到靶向治疗的作用,比如血液系统恶性肿瘤[51]...
③当brd4的表达水平<0.496和pd-1的表达水平<1.129时,和/或当brd4的表达水平<0.496和pd-l1的表达水平<0.382时,aml患者临床预后好的可能性较大。 一种预测aml预后的试剂盒,包括用于扩增pd-1cdna的引物和用于扩增pd-l1cdna的引物中的一种或两种,和用于扩增brd4cdna的引物。
bet抑制剂与抗pd-1或抗pd-l1药物联合使用时,能够在全身起作用的同时,激发局部抗肿瘤免疫,从而有效抑制肿瘤生长。在前列腺癌小鼠模型中,jq1联合抗ctla-4药物治疗被观察到提高了cd8/treg细胞的比率。目前报道大多集中在brd4抑制剂与其他抗癌药的联合用药效果,但jq1单剂量治疗尚未得到较好的验证。对brd4的研究大多集中...
2、brd4能够促进肿瘤的发展和转移等过程,在黑色素瘤、骨髓瘤和乳腺癌等多种肿瘤中过表达。brd4的具体作用机制主要有:促进c-myc基因、b淋巴细胞瘤2基因的转录;上调肿瘤细胞中pd-l1的表达,促进肿瘤细胞增殖;加剧免疫抑制;修复损伤的dna;促进端粒延伸。brd4对肿瘤组织的重要作用使得此靶点成为药物研发的重点。
[217]. Another study showed that JQ1 upregulated PD-L1 expression in HCC cells by increasing Rab8A expression, thus promoting the immunotherapeutic effect of an anti-PD-L1 antibody on HCC cells [218]. In addition to JQ1, other BRD4 inhibitors have been used to treat hepatic fibrosis. Sarah...
[217]. Another study showed that JQ1 upregulated PD-L1 expression in HCC cells by increasing Rab8A expression, thus promoting the immunotherapeutic effect of an anti-PD-L1 antibody on HCC cells [218]. In addition to JQ1, other BRD4 inhibitors have been used to treat hepatic fibrosis. Sarah...
BRD4对高表达PD-L1非小细胞肺癌细胞表达及增殖迁移的影响 目的:探讨BRD4对高表达程序性死亡受体配体1(PD-L1)非小细胞肺癌细胞PD-L1的表达及增殖迁移的影响.方法:通过GEPIA中TCGA数据库,获取有关于非小细胞肺癌患者的相关数据,... 姜剑松,王晨路,朱曼旎,施敏骅 被引量: 0发表: 2023年 加载更多研究...